CCO Annual Update
Prostate Cancer Annual Update 2006
Epidemiology, Screening, and Biomarkers for Prostate Cancer
|
Module 1 of 8
|
Program Director:
E. David Crawford, MD
|
|
 A discussion of current and relevant data on the prostate cancer epidemiology and trends in screening and prognostic techniques Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss international trends and patterns for prostate cancer, with special emphasis on the epidemiology of this disease in the US population
- Describe the advantages and disadvantages of PSA screening
- Summarize ongoing studies involving novel biomarkers for prostate cancer
|
Treatment of Localized Disease
|
Module 2 of 8
|
Program Director:
E. David Crawford, MD
|
|
A current discussion on the treatment of localized prostate cancer Learning Objectives
Upon completion of this activity, participants should be able to:
- Review recent developments for assessing risk in patients with newly diagnosed, clinically localized prostate cancer
- Describe factors affecting disease prognosis
- Evaluate newer treatment strategies for localized disease, including active surveillance and focal therapy
|
Prevention and Complementary/Alternative Medicines
|
Module 3 of 8
|
Program Director:
E. David Crawford, MD
|
|
Up-to-date review of complementary and alternative therapies for prostate cancer Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe common complementary and alternative therapies, and the rationale, if any, for their use
- Summarize the results of large prostate cancer prevention trials and the potential controversies that surround the trials
- Discuss staging nomograms and the concept of predicting indolent disease
|
Recent and Future Directions of Hormonal Therapy in Prostate Cancer
|
Module 4 of 8
|
Program Director:
E. David Crawford, MD
|
|
A discussion of current data and developing trends for hormonal therapy in prostate cancer Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the strengths and limitations of studies on the use of androgen-deprivation therapy (ADT) in early-stage prostate cancer
- Explain the implications of ongoing and pending national trials that will define the use of ADT in combination with chemotherapy
- Review the rationale behind the use of ADT combined with targeted drugs or vaccine therapies in future studies
|
Monitoring Response, Prediction Methodology, Staging, and Imaging in Prostate Cancer
|
Module 5 of 8
|
Program Director:
E. David Crawford, MD
|
|
An analysis of current state of monitoring and predicting response to treatment, disease staging, and imaging in the prostate cancer setting Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the utility of various PSA measures in assessing present and future risk of prostate cancer
- Describe the utility of nomograms for assessment of indolent disease
- Discuss the strengths and weaknesses of current staging and imaging techniques and their accuracy in stratifying patients with newly diagnosed prostate cancer
|
New Frontiers in the Management of Hormone-Refractory Prostate Cancer
|
Module 6 of 8
|
Program Director:
E. David Crawford, MD
- Nicholas J. Vogelzang, MD
|
|
|
Current and future trends in the management of hormone-refractory prostate cancer are reviewed, including novel chemotherapy combinations, targeted agents, and immunotherapy. Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize potential efficacy and safety of recent therapeutic approaches for managing hormone-refractory prostate cancer
- Describe the role of novel targeted therapies in the overall treatment of advanced prostate cancer
- Review the latest data on the use of immunotherapy in hormone-refractory prostate cancer
|
Treatment-Related and Disease-Related Complications in Prostate Cancer
|
Module 7 of 8
|
Program Director:
E. David Crawford, MD
|
|
Overview of recent data on the management- and disease-related complications in the prostate cancer setting. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss bone-related complications associated with prostate cancer and its treatment
- Describe the prevalence and prevention of genitourinary complications that occur with various prostate cancer treatment modalities
- Review health-related quality-of-life issues in prostate cancer patients
|
New Techniques and Management Options
|
Module 8 of 8
|
Program Director:
E. David Crawford, MD
|
|
An up-to-date discussion of novel chemotherapeutic, targeted, and surgical techniques for the management of prostate cancer Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the latest clinical trial data that support the use of docetaxel-based therapy for the treatment of patients with hormone-refractory prostate cancer (HRPC)
- Review the potential of new agents being tested for the treatment and management of HRPC
- Describe the various techniques available for the treatment of localized prostate cancer
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|